EssilorLuxottica, parent of the Okaley,, Supreme, Ray-Ban, Costa and Native Eyewear, and MidEuropa entered into an agreement with Optegra to acquire the ophthalmology platform, which operates in five key European markets: the UK, Czech Republic, Poland, Slovakia, and the Netherlands. This acquisition builds on the company’s existing offering, which includes AI-powered technologies, wearables, medical devices, and eyecare solutions.
The Optegra group, operating under the Optegra, Lexum, and Iris brands, has a network of over 70 eye hospitals and diagnostic facilities across Europe.
The group offers “medically necessary ophthalmic treatments and elective vision correction procedures, supported by AI in both pre- and post-operative stages,” said the company
“With the acquisition of Optegra, we are stepping into a new frontier—one where comprehensive eyecare, advanced diagnostics, therapeutic interventions, and surgical treatments come together in one seamless platform,” said Francesco Milleri, chairman and chief executive officer, and Paul du Saillant, deputy chief executive officer at EssilorLuxottica. “We have the strategic assets to fuel this vision: an extensive distribution network with new clinical approaches, a smart eyewear offering with health care potential, and diagnostic capabilities that will be able to detect conditions ranging from neurodegenerative diseases to cardiovascular dysfunction.”
The two executives added, “Optegra and its experienced doctors will bring new medical capabilities to our group, enabling us to address patients’ needs with the most advanced vision care technologies and treatments in one trusted system that will anchor our med-tech aspirations. Powered by our growing AI and big data capabilities, we will be able to broaden our impact and deliver the most personalized and seamless patient journey.”
“Joining forces with EssilorLuxottica marks a transformative chapter for Optegra. Their global leadership in vision care, combined with our clinical excellence and patient-centric approach, creates an innovative platform to redefine the paradigm of ophthalmic services,” commented Dr. Peter Byloos, chief executive officer of Optegra Eye Health Care. “This partnership not only accelerates our growth potential but also enhances our ability to deliver advanced, digital and integrated eyecare solutions to all our patients. It also creates a significant opportunity for our clinical team, our staff and leadership to be part of a global and inspiring leader in vision care.”
“Optegra’s evolution under MidEuropa’s ownership reflects our approach to supporting high-quality European healthcare platforms with strong growth potential,” said Robert Knorr, managing partner at MidEuropa. “We believe EssilorLuxottica is the ideal partner to lead Optegra into its next phase of growth and innovation, and we wish them every success as they build on the strong foundation we have helped create.”
The transaction is expected to close later in 2025, pending receipt of regulatory approvals and other customary closing conditions. Financial terms of the acquisition were not disclosed.
Image courtesy EssilorLuxottica
